(Total Views: 572)
Posted On: 04/14/2020 7:39:25 AM
Post# of 155790
Thought this part of the article was interesting...
CytoDyn on April 13 appointed its Chairman, Scott A. Kelly, MD, to the additional position of Chief Medical Officer and Head of Busines Development, a move it said would accelerate evaluation of leronlimab for COVID-19 and other indications
Is this just the fact that we have a full time CMO so the FDA would take us more seriously?
CytoDyn on April 13 appointed its Chairman, Scott A. Kelly, MD, to the additional position of Chief Medical Officer and Head of Busines Development, a move it said would accelerate evaluation of leronlimab for COVID-19 and other indications
Is this just the fact that we have a full time CMO so the FDA would take us more seriously?
(0)
(0)
